Latest News

 

Munroe Regional Medical Center Performs 100th TIF Procedure

 

Published Friday, May 8, 2009

by Chip Hennen

Redwood City, CA (May 7, 2009)EndoGastric Solutions (EGS), the recognized leader in the emerging field of Natural Orifice Surgery (NOS), today announced that Munroe Regional Medical Center, in Ocala, Florida, has performed 100 TIF (Transoral Incisionless Fundoplication) procedures for the treatment of chronic acid reflux, or gastroesophageal reflux disease (GERD), with the innovative EsophyX® surgical device. Munroe Regional Medical Center has completed over 200 Natural Orifice Surgery procedures including both TIF and StomaphyX procedures, and is the first hospital in Florida to achieve the 100 TIF cases milestone.

"We are pleased to be on the leading edge of the incisionless surgery revolution,” said Kevin Hoddinott, MD, who performs TIF procedures at Munroe. “There are tens of millions of patients that are taking acid suppressing medications and continuing to suffer with chronic reflux. TIF is a surgical solution without the long-term complications, prolonged recovery and other downsides of traditional GERD surgery. We are proud to be the first medical center in Florida in the TIF Century Club.”

“We are honored to recognize this landmark achievement by Munroe,” stated Thierry Thaure, President and Chief Executive Officer of EndoGastric Solutions. “This milestone underscores the significant patient need and benefits offered by the TIF procedure. TIF is unique in that it is completely incisionless surgery that corrects the anatomic cause of reflux. TIF has been proven safe, effective and durable, and it offers patients reduced discomfort and rapid recovery. We are making progress in expanding patient access to the benefits of TIF surgery in the U.S. and around the world.”


About EndoGastric Solutions
EndoGastric Solutions, Inc., is a privately held corporation located in Redmond, Washington, and Redwood City, California. EGS is a pioneer in developing incisionless transoral procedures for the treatment of upper gastrointestinal conditions, including gastroesophageal reflux disease (GERD). EsophyX and StomaphyX are cleared by the FDA, CE marked, and available for sale in the U.S. and other parts of the world.

For more information about EndoGastric Solutions and EsophyX:
http://www.endogastricsolutions.com/

PRESS CONTACT:
Chip Hennen
Marketing Department
EndoGastric Solutions, Inc.
(650) 226-2236
chennen@endogastricsolutions.com

CUSTOMER CONTACT:
Tom Dempsey
Sales Department
EndoGastric Solutions, Inc.
(303) 324-1168
tdempsey@endogastricsolutions.com

EUROPEAN CUSTOMER CONTACT:
Karl Blohm
General Manager, EGS Europe
+33 6 7525 8382
kblohm@endogastricsolutions.com

NP01897-01A

###

 

Request Info button

 

NP01366-01B